Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease

Circulation

Volumn 117, Issue 2, 2008, Pages 163-168

  Tonelli, Marcello ^a   Sacks, Frank ^b   Arnold, Malcolm ^c   Moye, Lemuel ^d   Davis, Barry ^d   Pfeffer, Marc ^e  

^a UNIVERSITY OF ALBERTA   (Canada)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Follow up studies; Mortality; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; ERYTHROCYTE VOLUME; FEMALE; HEART FAILURE; HEART INFARCTION; HEMATOCRIT; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RED BLOOD CELL DISTRIBUTION WIDTH; RISK ASSESSMENT; RISK FACTOR; STROKE;

EID: 38049148378     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.727545     Document Type: Article

References (16)

1. Perkins SL. Examination of blood and bone marrow. In: Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraksevas F, Glader BE, eds. Wintrobe's Clinical Hematology. 11th ed. Salt Lake City, Utah: Lippincott Wilkins & Williams; 2003:5-25.
2. McKenzie SD. Introduction to anemia. In: McKenzie SD, ed. Clinical Laboratory Hematology. Saddle River, NJ: Pearson Prentice-Hall; 2003:161-188.
3. Felker GM, Allen LA, Pocock S, Shaw LK, McMurray JJV, Pfeffer MA, Swedberg K, Wang D, Yusuf Y, Michelson EL, Granger C; CHARM Investigators. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank for Cardiovascular Diseases. J Am Coll Cardiol. 2007;50:40-47.
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1008.
5. Sacks FM, Pfeffer MA, Moye L, Brown LE, Hamm P, Cole TG, Hawkins CM, Braunwald E. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE). Am J Cardiol. 1991;68:1436-1442.
6. NKF-K/DOQI clinical practice guidelines for chronic kidney disease. Am J Kidney Dis. 2002;39(suppl 1):S76.
7. Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ. 2006;332:1426-1430.
8. Nieto FJ, Coresh J. Adjusting survival curves for confounders: a review and a new method. Am J Epidemiol. 1996;143:1059-1062.
9. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E; Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98:839-845.
10. Collins AJ, Li S, St Peter W, Ebben J, Roberts T, Ma JZ, Manning W. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001;12:2465-2470.
11. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, Knudtson ML. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol. 2004;44:1587-1592.
12. Cantaro S, Piva E. Hematological and iron parameters to predict mortality in ESRD [in Italian]. G Ital Nefrol. 2005;22(suppl 31):S135-S139.
13. Duffy TP. Approach to the patient with anemia. In: Kelley WN, Dupont HL, Glick JH, Harris ED, Hathaway DR, Hazzard WR, Holmes EW, Hudson LD, Humes HD, Paty DW, eds. Kelley's Textbook of Internal Medicine. 3rd ed. Philadelphia, Pa: Lippincott Williams and Wilkins; 1997:1295-1299.
14. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AMJ. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-1965.
15. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290:2945-2951.
16. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011-1023.